<DOC>
	<DOCNO>NCT00576459</DOCNO>
	<brief_summary>This 3-year randomized , dose mask , three-arm control , pilot study evaluate safety efficacy intravitreal FA implant ( 0.59mg 2.1mg ) , compare laser photocoagulation treatment patient diabetic macular edema .</brief_summary>
	<brief_title>Safety Efficacy Intravitreal Fluocinolone Acetonide Implants Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Subjects type 1 2 diabetes . Subjects clinically significant macular edema define ETDRS . A best correct visual acuity +0.30 +1.00 logMAR ( 70 35 letter approximately 20/40 20/200 ) measure ETDRS chart . Subjects laser treatment status/history follow : [ 1 ] Naïve laser photocoagulation Focal laser photocoagulation 16 week prior screen PRP 24 week prior screen , [ 2 ] No laser scar within 500µm ( 4x width retinal vein disc margin ) central macula . The subject 's ocular medium sufficiently clear allow quality fundus photography . If aphakic pseudophakic , lens removal occur least 40 week prior screen . Subjects males nonpregnant female least 18 year . Subjects display ability willingness comply treatment , follow process , sign Informed Consent Form . Subjects previous grid macular photocoagulation diffuse macular edema . Presence posterior hyaloid membrane , epiretinal membrane , fibrovascular proliferation , vitreopapillary traction , cause tractional distortion macula demonstrate OCT funduscopy . History current retinal detachment require surgical treatment scleral buckle . Diabetic Retinopathy require immediate PRP . Ocular disease diabetic retinopathy could confound outcome study ( e.g. , agerelated macular degeneration , drug toxicity , uveitis , hypertensive retinopathy , ischemic maculopathy , etc. ) . Glaucoma , history glaucoma either study eye fellow eye . Ocular hypertension , history ocular hypertension require IOP lower treatment . A medium opacity preclude visualization and/or diagnosis status eye . Concurrent coumadin therapy know bleeding diathesis . Subjects require chronic systemic corticosteroid therapy systemic immunosuppressive therapy manage nonocular disease . Concurrent treatment new investigational drug . Subjects bestcorrected visual acuity bad +1.0 logMAR ( 20/200 35 ETDRS letter ) fellow eye . Pregnant lactating female . Females childbearing potential consider become pregnant course study take effective contraception/precautions avoid pregnancy . History hypersensitivity fluorescein , know allergy steroid component intraocular device . Subjects photophobia preclude ability fundus evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>